No insider purchase over the last 90 days. The latest was filed 20 May 2026.
This page follows insider dealings at Oncoinvent ASA as filed with Oslo Børs, a company from the Health Care sector. From 18 October 2025 to 18 October 2026, the disclosure feed for Oncoinvent ASA logged 12 filings by 9 insiders.
Not one open-market sale was filed. On the buying side, 2 insiders reported 2 purchases. No amount is published for 2 filings, which the totals therefore leave out. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant.
Across the 258 companies tracked on its exchange, the median is 4 filings; at 12 filings, this issuer sits above that mark. Our records for Oncoinvent ASA go back to 2021, with 8 purchases and 4 sales on the open market in total.
The last purchase on record was published on 20 May 2026, which is 150 days ago.
Elsewhere in the same sector, our signals recently picked up insider purchases at Anixa Biosciences Inc and Vivos Inc. This summary is built from Oslo Børs disclosures alone and does not predict where the share price will go.
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
FY ended December 2025 · cache
25 of 31 declarations
Oncoinvent ASA is a Norwegian company focused on developing innovative cancer treatments. It is listed on the Oslo Stock Exchange (XOSL).
Purchases our model currently ranks for the recommendations list.
All recommendations